CATEGORIES: CMT Update
Resistance-Type Exercise Training

A Bi-Directional, Translational Model of Resistance-Type Exercise Training in the Management of Charcot-Marie-Tooth (CMT) Disease

by | Aug 18, 2015 | 3 comments

Resistance-Type Exercise Training

A team of government researchers, including Dr. Robert Chetlin (Associate Professor and Clinical Director of Sports Medicine at Mercyhurst University, Research Physiology Contractor in the Division of Safety Research at CDC-NIOSH), have collaborated with Dr. Michael Sereda and Dr. Klaus Nave of the Max Planck Institute for Experimental Medicine (MPI) to successfully secure the CMT1A transgenic rat from MPI and establish a colony in the United States. Presently. Initial funding for this project was supported by the Hereditary Neuropathy Foundation (HNF, New York, NY).

These government investigators, including Dr. Chetlin, are continuing to examine the effects of a validated, evidence-based mechanical loading “resistance-type” exercise protocol on these transgenic CMT1A rats. These unique animals are trained on a specialized machine, called a dynamometer (a machine used to exercise and test force, torque, and power), using stretch-shortening contractions (SSCs; coordinated muscle lengthening and shortening movements used daily in human and animal activities).

The animals’ exercise routine is very tightly controlled, including all the training variables, such as the volume (reps and sets), intensity (how hard), duration (time per training session), frequency (number of training sessions per week), and progression (training variable increases) of exercise. The extent to which the animals had beneficially adapted to the exercise training was determined upon completion of the “resistancetype” training protocol. An integrated systems approach was utilized to examine and quantify exerciseinduced changes in:

(1) functional performance of muscle, including strength and muscular work;

(2) muscle physiology and quality and individual myofiber histomorphology (microscopic examination of muscle anatomy, function, and pathology);

(3) the nerve coating (myelin), connection between nerve and muscle (neuromuscular junction), and the nerve itself, and;

(4) the genes, proteins, and other potential “biomarkers” that may exert control over the way muscles and nerves operate and communicate with each other in response to exercise.

Collectively, these initial findings suggest that SSC-exercise training may be the preferred mode of resistance-type training, given that it enhanced static and dynamic muscle performance and muscle quality. This provides evidence suggesting that when an established fundamental model of CMT1A is mechanically loaded, using a validated, in vivo, highintensity, “resistance-type” training regimen, a dynamic adaptive response results.

This occurrence may represent a critical direction for establishing an achievable translational paradigm for increased quality-of-life and independence in human CMT patients. To our knowledge, this is the first study to integrate an established animal model of CMT and investigate the effects of a validated and adaptive, resistance-type exercise training regimen on PMP22 gene expression in muscle for any animal or human CMT population.

Given the course of these experiments, we now intend to refine the exercise exposure to identify the type, quantity, and frequency of training that provides optimal functional benefit to the transgenic CMT1A rats. Additionally, future studies will also examine the possible effects of dietary supplements, and other small-molecule therapies in the transgenic rats, with and without exercise, to determine if the combination of exercise and these other interventions are more effective than any of these approaches used alone.

A synopsis of the most recent findings, presented at the 2015 Annual Meeting of the American College of Sports Medicine (ACSM), includes:

• SSC-exercise training protocol of 4.5 weeks duration (~6-month human equivalent), employing dynamic SSCs, elicits an adaptive response in transgenic CMT1A rats.

The training-related adaptive performance and physiological response improved relative isometric force production (static strength), maintenance of normalized muscle mass (a ratio of examined muscle mass to limb length), and a trend for improved static muscle quality (a ratio of isometric force to normalized muscle mass).

• Improved dynamic (SSC) muscle function indicated by an increase in positive work and a trend for increased cyclic force (repeated SSC force); while, additionally, there was an enhancement in dynamic muscle quality (a ratio of SSC force to normalized muscle mass).

• SSC-exercise training reduced PMP22 gene (the gene which codes for myelin production; mutations of this gene may result in CMT1A, Dejerine-Sottas Disease, or Hereditary Neuropathy with liability to Pressure Palsy) expression, which may, ultimately, improve myelin integrity (and function) in these SSCtrained animals.

Disclaimer: The information presented in this article has previously been disseminated to the public at the 2015 and the National Conference of the American College of Sports Medicine. HNF, in part sponsored this research project

Learn more on this topic

Related Blog Posts

Double Your Donation

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Taking Matters Into Your Own Hands

Do you have a rare form of CMT?

We were contacted recently from a patient with CMT2D who was looking for advice on how to make a difference. Our recommendations for all people with an ultra-rare form of CMT who want to get involved:

Now GRIN is Accessible in 141 Different Languages!

Now GRIN is Accessible in 141 Different Languages!

The Global Registry for Inherited Neuropathies (GRIN) has implemented Google Translate. Why did we choose Google? Because Google is leading the way in teaching computers how to interpret meaning, avoiding the traditional method of decoding language.

Accelerating Patient Access to Investigational Drugs in 2015

Accelerating Patient Access to Investigational Drugs in 2015

Currently the FDA is working to update the process for physicians applying for accelerated patient access to investigational drugs, while the drug or biological product is being tested in clinical trials. This will also be important for the CMT community as clinical trials for this disease are being launched.

Do You Have Charcot-Marie-Tooth Type 4 (CMT4)? – We Need Your Help

Autosomal recessive demyelinating CMT4 patients present with earlyonset and slowly progressing symptoms. These include progressive distally accentuated weakness and atrophy of muscles in the lower limbs. In addition, patients may have weakness and atrophy of hands, sensory loss and pes cavus (high-arched feet), and walking difficulties. Further information on CMT4 can be found at Orphanet.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Join the conversation

Leave a Comment

3 Comments

  1. Joyce Rall

    How do I find a doctor and physical therapist trained for neuropathy in my area.
    I have been to many different doctors with no results.

    Reply
  2. Robert Simo

    Where can I go to train doing these exercise is there a certain place in New Jersey thanks

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news